Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SL-172154 with PLD or mirvetuximab in platinum-resistant ovarian cancer
NCT05483933Phase 1Completed
- Sponsor
- Shattuck Labs
- Start
- Aug 2022
- Primary completion
- Feb 2025
- Modality
- Fc-Fusion Proteins
- Countries
- 4
01
Overview
Phase 1, open-label trial of SL-172154 in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal carcinoma (PPC) (2 arms), sponsored by Shattuck Labs. Primary endpoints: Safety and Tolerability of SL-172154 When Administered With PLD or Mirvetuximab at 6 months and Recommended Phase 2 Dose at 6 months. Started Aug 2022; status: completed.
02
Drugs
SL-172154
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal carcinoma (PPC)
Beyond the preview
Go deeper on NCT05483933.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05483933.